The biotechnology business in India with an increase from USD 500 million in 1997 and reaching an estimated USD I billion next year health related prod ucts accounting for 60%, agro and veterinary products together 15%, and con tract R&D, reagents, devices and supplies adding up to the remaining 25% of which the diagnostics share was about 10% of the total surely presented an encouraging picture even five years ago. While volumes have increased, the pat tern has not. According to a report, prepared by McKinsey & Co, India's Phar maceutical industry including domestic and export sales and contract services totals nearly USD 5 billion. Furthermore, the company optimistically projects the growth to a factor of five fold only if both the industry and the government are able to put in place achievable solutions that must take care of the formida ble obstacles preventing further growth. If this assessment is correct, then the established transformation made by IT growth should also provide the confi dence required by the high expectations for biotechnology which have arisen in the country in recent years. Some contributors to this are overenthusiastic these are bureaucrats, some retired scientists and of course the complacent politicians who have the least knowledge of what the new biotechnology is all about. However, there are clear indications of biotechnology growth demon strated by a few but rapidly expanding biotech companies such as Biocon Ltd, Shantha Biotech (P) Lid, Dr.

The biotechnology business in India with an increase from USD 500 million in 1997 and reaching an estimated USD 1 billion next year health related prod ucts accounting for 60%, agro and veterinary products together 15%, and con tract R&D, reagents, devices and supplies adding up to the remaining 25% of which the diagnostics share was about 10% of the total surely presented an encouraging picture even five years ago. While volumes have increased, the pat tern has not. According to a report, prepared by McKinsey & Co, India's Phar maceutical industry including domestic and export sales and contract services totals nearly USD 5 billion. Furthermore, the company optimistically projects the growth to a factor of five fold only if both the industry and the government are able to put in place achievable solutions that must take care of the formida ble obstacles preventing further growth. If this assessment is correct, then the established transformation made by IT growth should also provide the confi dence required by the high expectations for biotechnology which have arisen in the country in recent years. Some contributors to this are overenthusiastic these are bureaucrats, some retired scientists and of course the complacent politicians who have the least knowledge of what the new biotechnology is all about. However, there are clear indications of biotechnology growth demon strated by a few but rapidly expanding biotech companies such as Biocon Ltd, Shantha Biotech (P) Ltd, Dr.

Foundations of data organization is a relatively new field of research in comparison to, other branches of science. It is close to twenty years old. In this short life span of this branch of computer science, it has spread to all corners of the world, which is reflected in this book. This book covers new database application areas (databases for advanced applications and CAD/VLSI databases), computational geometry, file allocation & distributed databases, database models (including non traditional database models), database machines, query processing & physical structures for relational databases, besides traditional file organization (hashing, index file organization, mathematical file organization and consecutive retrieval property), in order to identify new trends of database research. The papers in this book originally represent talks given at the International Conference on Foundations of Data Organization, which was held on May 21-24, 1985, in Kyoto, Japan. This conference was held at Kyoto University, and sponsored by the organizing committee of the International Conference on Foundations of Data Organization and the Japan Society for the Promotion of Science. The conference was in cooperation with: ACM SIGMOD, IEEE Computer Society, Information Processing Society of Japan, IBM Research, Kyushu University, Kobe University, IBM Japan, Kyoto Sangyo University and Polish Academy of Sciences. This Conference was the follow-up of the first conference, which was hosted by the Polish Academy of Sciences and held at Warsaw in 1981. The Warsaw conference focused mainly on consecutive retrieval property and it's applications."

The biotechnology business in India with an increase from USD 500 million in 1997 and reaching an estimated USD I billion next year health related prod ucts accounting for 60%, agro and veterinary products together 15%, and con tract R&D, reagents, devices and supplies adding up to the remaining 25% of which the diagnostics share was about 10% of the total surely presented an encouraging picture even five years ago. While volumes have increased, the pat tern has not. According to a report, prepared by McKinsey & Co, India's Phar maceutical industry including domestic and export sales and contract services totals nearly USD 5 billion. Furthermore, the company optimistically projects the growth to a factor of five fold only if both the industry and the government are able to put in place achievable solutions that must take care of the formida ble obstacles preventing further growth. If this assessment is correct, then the established transformation made by IT growth should also provide the confi dence required by the high expectations for biotechnology which have arisen in the country in recent years. Some contributors to this are overenthusiastic these are bureaucrats, some retired scientists and of course the complacent politicians who have the least knowledge of what the new biotechnology is all about. However, there are clear indications of biotechnology growth demon strated by a few but rapidly expanding biotech companies such as Biocon Ltd, Shantha Biotech (P) Lid, Dr.

The biotechnology business in India with an increase from USD 500 million in 1997 and reaching an estimated USD 1 billion next year health related prod ucts accounting for 60%, agro and veterinary products together 15%, and con tract R&D, reagents, devices and supplies adding up to the remaining 25% of which the diagnostics share was about 10% of the total surely presented an encouraging picture even five years ago. While volumes have increased, the pat tern has not. According to a report, prepared by McKinsey & Co, India's Phar maceutical industry including domestic and export sales and contract services totals nearly USD 5 billion. Furthermore, the company optimistically projects the growth to a factor of five fold only if both the industry and the government are able to put in place achievable solutions that must take care of the formida ble obstacles preventing further growth. If this assessment is correct, then the established transformation made by IT growth should also provide the confi dence required by the high expectations for biotechnology which have arisen in the country in recent years. Some contributors to this are overenthusiastic these are bureaucrats, some retired scientists and of course the complacent politicians who have the least knowledge of what the new biotechnology is all about. However, there are clear indications of biotechnology growth demon strated by a few but rapidly expanding biotech companies such as Biocon Ltd, Shantha Biotech (P) Ltd, Dr.